The AI system for healthcare research.
Analyze research data securely, on hardware you own.
Sensitive research, handled in house.
GEM can review studies, train models, screen scans and draft protocols on your own Cube.
Review the 2,400 patient records from Study 14 and flag adverse events above baseline.
Read 2,400 records, compared to baseline, flagged 3 events
2,400 records reviewed. Three adverse events are above baseline, all in the treatment cohorts.
| EVENT | COHORT | VS BASELINEVS BASE. |
|---|---|---|
| Elevated liver enzymes | Cohort B | 2.4x |
| Grade 2 headache | Cohort A | 1.8x |
| Injection site reaction | Cohort B | 1.6x |
Find every published trial on our compound class since 2015 and summarize the cardiac safety findings.
Searched 1,860 papers, found 42 trials, summarized findings
42 trials found. 38 report no added cardiac risk. Four report a small rise at the highest dose, all after 12 months.
| TRIAL | PATIENTS | CARDIAC FINDING |
|---|---|---|
| Phase III, high dose arm | 3,120 | Small rise after 12 mo |
| Long-term extension study | 1,840 | Small rise after 18 mo |
| Phase II dose finding | 412 | No added risk |
Fine-tune our pathology model on the 18,000 annotated slides from the last two years.
Prepared 18,000 slides, started training job, checked loss
Training is on epoch 2 of 3. Validation loss is down to 0.412 and still falling, with about an hour left.
Screen last month's 3,200 chest CTs and flag any with nodules over 6 mm for radiologist review.
Read 3,200 scans, measured nodules, flagged 11 for review
3,200 scans screened. 11 show nodules over 6 mm and are queued for radiologist review, largest first.
| SCAN | LOCATION | NODULE |
|---|---|---|
| CT 2291, Oct 14 | Right upper lobe | 11 mm |
| CT 1874, Oct 9 | Left lower lobe | 9 mm |
| CT 2045, Oct 11 | Right middle lobe | 7 mm |
More research, less risk.
- Study 14 · interim analysis Report Summarized
- Cohort B, 2,400 patient records Dataset Analyzed
- Manuscript draft, v7 Draft Reviewed
- Tumor grade classifier Model Trained on Cohort B
Unpublished work stays yours.
$0
18.6Mtokens across 3 jobs
- Screening 12,000 chest CT scans
- Fine-tuning on 18,000 pathology reports
- Reviewing 312 published studies
Costs that don't climb with every token.
OVERNIGHT BATCH
Chest CT screening, 12,000 scans
6:12 AM
6:12 AM
Chest CT screening
CompletedOvernight batch, 12,000 scans
Results ready by morning.
46 STUDIES SEARCHED · 5 MATCHES
- Study 9 38 patients
- Study 4 12 patients
- Study 11 9 patients
- Study 2 6 patients
- Study 7 4 patients
Ask across every study your lab has run.
The case for owning it.
- Data stays on your network.
- Ready to run the day it arrives.
- Add Cubes as your lab grows.
- Shared across your team.
Common questions.
Yes. Records stay on your network, and GEM processes them on the Cube, never on an outside provider's servers.
Clinical notes, trial datasets, pathology reports and published studies, alongside your own analysis files.
Yes. Fine-tune on your records right on the Cube, and the model stays on your hardware.
Yes. Access is set per study, so each team sees only its own records, and an Alpha Cube serves up to 600 people. Compare models
That identifiable data stays on hardware your institution controls and never goes to an outside AI provider.
Have another question? Get in touch
Own the AI behind your clinical research.
Keep every study private, with no token limits on what you run.
